Description

Metabolism. Evolution. Precision.

Crownwell Research introduces 15 mg GLP3-Reta, a cutting-edge formulation of the triple-hormone receptor agonist. Recognized in clinical research for its unprecedented affinity for GLP-1, GIP, and Glucagon receptors, GLP3-Reta represents the next evolution in metabolic and weight-regulation studies.

Our GLP3-Reta is synthesized to provide researchers with a high-stability peptide that offers multi-pathway signaling, ensuring reliable and reproducible data in complex metabolic research.
Available in various concentrations to suit specific research protocols, each vial is rigorously tested to ensure it meets or exceeds the 99% purity standard.

Product Highlights:

Triple-Action Synthesis: Formulated for high bioavailability across GLP-1, GIP, and GCG pathways.
Research Grade: Intended strictly for laboratory and scientific research use